Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Employees - 1271, CEO - William H. Lewis, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 11.76, Piotroski Score(max is 10): 3, Working Capital: $1769899000, Total Assets: $2479857000, Retained Earnings: $-4938186000, EBIT: -947136000, Total Liabilities: $1230122000, Revenue: $398105000

AryaFin Target Price - $-91.47 - Current Price $ - Analyst Target Price $